<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585505</url>
  </required_header>
  <id_info>
    <org_study_id>PGI NUC MED</org_study_id>
    <nct_id>NCT02585505</nct_id>
  </id_info>
  <brief_title>Tissue Distribution of F18-FDG Labeled ABMSCT in Patients With Type2 Diabetes Mellitus</brief_title>
  <official_title>Tissue Distribution of F18-FDG Labeled Autologous Bone Marrow Derived Stem Cells in Patients With Type2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stem cells have promising potential in treating diabetes. However the therapeutic outcome in
      diabetic patients will profoundly depend on their delivery to pancreas. Our objective is to
      label stem cells with PET tracer F18-FDG to carry out in vivo cell tracking. The labeled stem
      cells will be given through different routes (intravenous and intraarterial)and tissue
      distribution studied. Patients will be followed up for the next 6 months. Glucagon stimulated
      C peptide will be measured at baseline and at 6 months and HOMA IR and HOMA beta will be
      calculated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our objective is to label stem cells with PET tracer F18-FDG to carry out in vivo cell
      tracking. The labeled stem cells will be given through different routes (intravenous and
      intraarterial)and tissue distribution studied. Patients will be followed up for the next 6
      months. Glucagon stimulated C peptide will be measured at baseline and at 6 months and HOMA
      IR and HOMA beta will be calculated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in glucagon stimulated C peptide level</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <arm_group>
    <arm_group_label>Intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>stem cells will be injected through intravenously in the subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>superior pancreaticoduodenal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>splenic artery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>stem cells will be injected through splenic in the subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>stem cells</intervention_name>
    <description>stem cell will be injected</description>
    <arm_group_label>Intravenous</arm_group_label>
    <arm_group_label>superior pancreaticoduodenal</arm_group_label>
    <arm_group_label>splenic artery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Patients with type 2 diabetes mellitus between 30 and 65 years of age.

               -  Duration of diabetes ≥ 5 years.

               -  Failure to triple OHA in optimal doses {glimepiride (4 gm), metformin(2-2.5 gm)
                  and pioglitazone(15mg)}.

               -  Requiring insulin therapy for last six month

               -  On stable doses of insulin (≥0.4 IU/kg/day, Vildagliptin, metformin (2 gm),
                  pioglitazone (15mg) for last three months.

               -  GAD antibody negative status.

        Exclusion Criteria:

          -  Patients with type 1 diabetes mellitus or secondary diabetes

          -  Patients with serum creatinine &gt; 1.5 mg/dL

          -  Abnormal liver function tests (defined as value of transaminases &gt; 3 times the upper
             value of normal or serum bilirubin higher than normal for the reference value for the
             laboratory).

          -  History of cholecystitis/ cholelithiasis/ cholecystectomy.

          -  Seropositivity for HIV, HBsAg and HCV.

          -  History of myocardial infarction or unstable angina or any cardiovascular events in
             the previous 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>October 22, 2015</last_update_submitted>
  <last_update_submitted_qc>October 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Anil Bhansali</investigator_full_name>
    <investigator_title>Head, Dept of Endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

